---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-051845"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T06:33:40.130720+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Karyopharm reports FY2023 total rev $146M, XPOVIO net $112M; guides 2024 total $140-160M

## Summary
- Full year 2023 total revenue $146.0M (down from $157.1M YoY); net loss $143.1M ($1.25/sh) vs $165.3M loss in 2022.
- Q4 2023 XPOVIO net product revenue $25.1M; full year $112.0M, down ~7% YoY due to competition and PAP utilization.
- Three pivotal Phase 3 top-line readouts expected in 2025: endometrial cancer, myelofibrosis, multiple myeloma.
- 2024 guidance: total revenue $140-160M, XPOVIO net $100-120M, R&D+SG&A $260-280M, cash runway to late 2025.
- Cash, equivalents and investments $192.4M as of Dec 31, 2023 vs $279.7M a year earlier.

## SEC filing metadata
- accession: 0001193125-24-051845
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312524051845/0001193125-24-051845-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312524051845/d774952d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-051845
- JSON: https://secwatch.observer/filing/0001193125-24-051845.json
- Plain text: https://secwatch.observer/filing/0001193125-24-051845.txt

## Key facts
- Earnings Releases
  Karyopharm Therapeutics Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue Total Revenue of $146 Million. Guidance reaffirmed.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Revenue: Total Revenue of $146 Million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress – Total Revenue of $146 Million and U.S. XPOVIO ® (selinexor) Net Product Revenue of $112 Million for Full Year 2023, Meeting Company’s Guidance
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312524051845/0001193125-24-051845-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.